Investigation of memory B cell responses to hepatitis B surface antigen in health care workers considered as non-responders to vaccination

Vaccine

Volumn 28, Issue 39, 2010, Pages 6411-6416

  Valats, J C ^a   Tuaillon, E ^a,b   Funakoshi, N ^a   Hoa, D ^c   Brabet, M C ^a   Bollore K ^a,b   Ducos, J ^a,b   Vendrell, J P ^a,b   Blanc, P ^a  

^a HÔPITAL SAINT ELOI   (France)

^b LAPEYRONIE HOSPITAL   (France)

^c IMAIOS   (France)

Author keywords

Hepatitis B; Memory B cell; Vaccination

Indexed keywords

HEPATITIS ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN G; RECOMBINANT HEPATITIS B VACCINE;

ADULT; ANTIBODY PRODUCTION; ANTIGEN DETECTION; ARTICLE; BLOOD ANALYSIS; CELLULAR IMMUNITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEALTH CARE PERSONNEL; HEPATITIS B; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LYMPHOCYTE DIFFERENTIATION; MALE; MEMORY CELL; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VACCINATION;

ADULT; B-LYMPHOCYTES; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HEALTH PERSONNEL; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED;

EID: 77956402479     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.07.058     Document Type: Article

References (52)

1. World Health Organization, http://www.who.int/csr/disease/hepatitis/HepatitisB_whocdscsrlyo2002_2.pdf.
2. Meffre C, Strat YL, Delarocque-Astagneau E. Estimation des taux de prévalence des anticorps anti-VHC et des marqueurs du virus de l'hépatite B chez les assurés sociaux du régime général de France métropolitaine; 2003-2004 [BEH-2005 janvier-2005].
3. Pruss-Ustun A., Rapiti E., Hutin Y. Estimation of the global burden of disease attributable to contaminated sharps injuries among health-care workers. Am J Ind Med 2005, 48(6 (December)):482-490.
4. Lemon S.M., Thomas D.L. Vaccines to prevent viral hepatitis. N Engl J Med 1997, 336(3 (January)):196-204.
5. Stewart A.M. Mandatory vaccination of health care workers. N Engl J Med 2009, 361(21 (November)):2015-2017.
6. Van Herck K., Vorsters A., Van Damme P. Prevention of viral hepatitis (B and C) reassessed. Best Pract Res Clin Gastroenterol 2008, 22(6):1009-1029.
7. EASL international consensus conference on hepatitis B. 13-14 September 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003, 38(4 (April)):533-540.
8. Immunisation against hepatitis B. Lancet 1988, 1(8590 (April)):875-876.
9. Puro V., De Carli G., Cicalini S., Soldani F., Balslev U., Begovac J., et al. European recommendations for the management of healthcare workers occupationally exposed to hepatitis B virus and hepatitis C virus. Euro Surveill 2005, 10(10 (October)):260-264.
10. Roome A.J., Walsh S.J., Cartter M.L., Hadler J.L. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA 1993, 270(24 (December)):2931-2934.
11. Averhoff F., Mahoney F., Coleman P., Schatz G., Hurwitz E., Margolis H. Immunogenicity of hepatitis B vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 1998, 15(1 (July)):1-8.
12. Platkov E., Shlyakhov E., Glick Y., Khalemsky S., Fischbein A. Immunologic evaluation of hepatitis B vaccine application in hospital staff. Int J Occup Med Environ Health 2003, 16(3):249-253.
13. Yen Y.H., Chen C.H., Wang J.H., Lee C.M., Changchien C.S., Lu S.N. Study of hepatitis B (HB) vaccine non-responsiveness among health care workers from an endemic area (Taiwan). Liver Int 2005, 25(6 (December)):1162-1168.
14. Saberifiroozi M., Gholamzadeh S., Serati A.R. The long-term immunity among health care workers vaccinated against hepatitis B virus in a large referral hospital in southern Iran. Arch Iran Med 2006, 9(3 (July)):204-207.
15. Hollinger F.B. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med 1989, 87(3A (September)):36S-40S.
16. Wood R.C., MacDonald K.L., White K.E., Hedberg C.W., Hanson M., Osterholm M.T. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 1993, 270(24 (December)):2935-2939.
17. Pasko M.T., Beam T.R. Persistence of anti-HBs among health care personnel immunized with hepatitis B vaccine. Am J Public Health 1990, 80(5 (May)):590-593.
18. McMahon B.J., Bruden D.L., Petersen K.M., Bulkow L.R., Parkinson A.J., Nainan O., et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005, 142(5 (March)):333-341.
19. Williams J.L., Christensen C.J., McMahon B.J., Bulkow L.R., Cagle H.H., Mayers J.S., et al. Evaluation of the response to a booster dose of hepatitis B vaccine in previously immunized healthcare workers. Vaccine 2001, 19(28-29 (July)):4081-4085.
20. Bauer T., Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 2006, 24(5 (January)):572-577.
21. Mintai Z., Kezhou L., Lieming D., Smego R.A. Duration and efficacy of immune response to hepatitis B vaccine in high-risk Chinese adolescents. Clin Infect Dis 1993, 16(1 (January)):165-167.
22. Banatvala J., Van Damme P., Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 2000, 19(7-8 (November)):877-885.
23. Wainwright R.B., Bulkow L.R., Parkinson A.J., Zanis C., McMahon B.J. Protection provided by hepatitis B vaccine in a Yupik Eskimo population-results of a 10-year study. J Infect Dis 1997, 175(3 (March)):674-677.
24. Are booster immunisations needed for lifelong hepatitis B immunity?. Lancet 2000, 355(9203 (February)):561-565. European Consensus Group on Hepatitis B Immunity.
25. Poorolajal J., Mahmoodi M., Majdzadeh R., Nasseri-Moghaddam S., Haghdoost A., Fotouhi A. Long-term protection provided by hepatitis B vaccine and need for booster dose: a meta-analysis. Vaccine 2010, 28(3):623-631.
26. Tuaillon E., Tabaa Y.A., Petitjean G., Huguet M.F., Pajeaux G., Fondere J.M., et al. Detection of memory B lymphocytes specific to hepatitis B virus (HBV) surface antigen (HBsAg) from HBsAg-vaccinated or HBV-immunized subjects by ELISPOT assay. J Immunol Methods 2006, 315(1-2 (August)):144-152.
27. Wismans P.J., van Hattum J., De Gast G.C., Endeman H.J., Poel J., Stolk B., et al. The spot-ELISA: a sensitive in vitro method to study the immune response to hepatitis B surface antigen. Clin Exp Immunol 1989, 78(1 (October)):75-79.
28. Bocher W.O., Herzog-Hauff S., Herr W., Heermann K., Gerken G., Meyer Zum Buschenfelde K.H., et al. Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection. Clin Exp Immunol 1996, 105(1 (July)):52-58.
29. Al Tabaa Y., Tuaillon E., Bollore K., Foulongne V., Petitjean G., Seigneurin J.M., et al. Functional Epstein-Barr virus reservoir in plasma cells derived from infected peripheral blood memory B cells. Blood 2009, 113(3 (January)):604-611.
30. Slifka M.K., Antia R., Whitmire J.K., Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998, 8(3 (March)):363-372.
31. Bernasconi N.L., Traggiai E., Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002, 298(5601 (December)):2199-2202.
32. Forrest B.D., LaBrooy J.T. Effect of parenteral immunization on the intestinal immune response to Salmonella typhi Ty21a as measured using peripheral blood lymphocytes. Vaccine 1993, 11(2):136-139.
33. Milich D.R., Leroux-Roels G.G. Immunogenetics of the response to HBsAg vaccination. Autoimmun Rev 2003, 2(5 (September)):248-257.
34. Weihrauch M.R., von Bergwelt-Baildon M., Kandic M., Weskott M., Klamp W., Rosler J., et al. T cell responses to hepatitis B surface antigen are detectable in non-vaccinated individuals. World J Gastroenterol 2008, 14(16 (April)):2529-2533.
35. Jarrosson L., Kolopp-Sarda M.N., Aguilar P., Bene M.C., Lepori M.L., Vignaud M.C., et al. Most humoral non-responders to hepatitis B vaccines develop HBV-specific cellular immune responses. Vaccine 2004, 22(27-28 (September)):3789-3796.
36. Larsen C.E., Xu J., Lee S., Dubey D.P., Uko G., Yunis E.J., et al. Complex cytokine responses to hepatitis B surface antigen and tetanus toxoid in responders, nonresponders and subjects naive to hepatitis B surface antigen. Vaccine 2000, 18(26 (July)):3021-3030.
37. Salazar M., Deulofeut H., Granja C., Deulofeut R., Yunis D.E., Marcus-Bagley D., et al. Normal HBsAg presentation and T-cell defect in the immune response of nonresponders. Immunogenetics 1995, 41(6):366-374.
38. Desombere I., Hauser P., Rossau R., Paradijs J., Leroux-Roels G. Nonresponders to hepatitis B vaccine can present envelope particles to T lymphocytes. J Immunol 1995, 154(2 (January)):520-529.
39. Vingerhoets J., Vanham G., Kestens L., Penne G., Leroux-Roels G., Gigase P. Deficient T-cell responses in non-responders to hepatitis B vaccination: absence of TH1 cytokine production. Immunol Lett 1994, 39(2 (February)):163-168.
40. Caillat-Zucman S., Gimenez J.J., Wambergue F., Albouze G., Lebkiri B., Naret C., et al. Distinct HLA class II alleles determine antibody response to vaccination with hepatitis B surface antigen. Kidney Int 1998, 53(6 (June)):1626-1630.
41. Wang R.X., Boland G.J., van Hattum J., de Gast G.C. Long-term persistence of T cell memory to HBsAg after hepatitis B vaccination. World J Gastroenterol 2004, 10(2 (January)):260-263.
42. Huzly D., Schenk T., Jilg W., Neumann-Haefelin D. Comparison of nine commercially available assays for quantification of antibody response to hepatitis B virus surface antigen. J Clin Microbiol 2008, 46(4 (April)):1298-1306.
43. Greub G., Zysset F., Genton B., Spertini F., Frei P.C. Absence of anti-hepatitis B surface antibody after vaccination does not necessarily mean absence of immune response. Med Microbiol Immunol 2001, 189(3 (April)):165-168.
44. Hofmann F., Kralj N. Criteria for successful hepatitis B vaccination in adults: results of a case study. Infection 2009, 37(3 (June)):266-269.
45. Boot H.J., van der Waaij L.A., Schirm J., Kallenberg C.G., van Steenbergen J., Wolters B. Acute hepatitis B in a healthcare worker: a case report of genuine vaccination failure. J Hepatol 2009, 50(2 (February)):426-431.
46. Bialek S.R., Bower W.A., Novak R., Helgenberger L., Auerbach S.B., Williams I.T., et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr Infect Dis J 2008, 27(10 (October)):881-885.
47. Potsch D.V., Oliveira M.L., Ginuino C., Miguel J.C., Oliveira S.A., Silva E.F., et al. High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects. Vaccine 2010, 28(6):1447-1450.
48. Rahman F., Dahmen A., Herzog-Hauff S., Bocher W.O., Galle P.R., Lohr H.F. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology 2000, 31(2 (February)):521-527.
49. Levin A. Dialysis: intradermal HBV vaccination is preferable in non-responders. Nat Rev Nephrol 2009, 5(11 (November)):616-617.
50. Ghebrehewet S., Baxter D., Falconer M., Paver K. Intradermal recombinant hepatitis B vaccination (IDRV) for non-responsive healthcare workers (HCWs). Hum Vaccin 2008, 4(4 (July-August)):280-285.
51. Jacques P., Moens G., Desombere I., Dewijngaert J., Leroux-Roels G., Wettendorff M., et al. The immunogenicity and reactogenicity profile of a candidate hepatitis B vaccine in an adult vaccine non-responder population. Vaccine 2002, 20(31-32 (November)):3644-3649.
52. Launay O., van der Vielt D., Rosenberg A., Michel M.-L., Lortholary O., Colin de Verdière N., et al. A randomized controlled trial comparing the efficacy and safety of four intramuscular double doses or four intradermal low doses with three intramuscular standard doses of hepatitis B vaccine in HIV infected adults: results of the ANRS HB03 VIHVAC-B trial. Conference on retroviruses and opportunistic infections (CROI) 2010, [MA Abstract 623 2010].